Eli Lilly introduced Mounjaro, a diabetes and weight-loss drug, in India, aiming to tackle obesity and diabetes. With a ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...

(MENAFN- Golin Mena) Bengaluru, March 20, 2025: Eli Lilly and Company (India) today announced the launch of Mounjaro® in single-dose vial presentation following the marketing authorization from ...

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro (tripeptide). The launch of this breakthrough medicine is an important step toward dealing ...

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous ...

Eli Lilly weight loss drug: Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. (Representative Image) Eli Lilly weight loss drug ...

A new study funded by Eli Lilly reports that people without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide. The study used Mounjaro, which is not yet approved ...

Eli Lilly and Company launched Mounjaro in single-dose vial presentation following the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). It is a first-of-its-kind ...

Eli Lilly and Company (India) on Thursday announced the launch of its globally popular weight-loss injectable drug, Mounjaro, in India. Adults taking the drug with diet and exercise in a ...